KalVista Pharmaceuticals ( KALV )

Share Interview Share Compensation

$60K Part D

LOE Approaching

Sole revenue driver (100% of company revenue) but losing exclusivity; limited Part D utilization suggests commoditization risk.

Help build intelligence for KalVista Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline focused on hereditary angioedema with Phase 3 programs (KVD900) likely to drive near-term value and clinical impact.
Recent acquisition by Chiesi Group ($1.64B) signals strategic validation and potential for expanded resources, integration opportunities, and new therapeutic areas.
Rare disease specialization in ophthalmology and angioedema offers deep scientific focus and smaller team dynamics typical of specialty pharma.

Watch Out For

Extreme revenue concentration (100% from AMICAR, an older product approaching loss of exclusivity) creates earnings vulnerability and limits career stability in commercial roles.
Negative net income ($−92.9M FY2025, $−82.3M FY2024) despite R&D spend of $86M and $70M respectively signals burn rate concerns; cash position ($32M FY2025) may tighten post-acquisition integration.
Zero active job postings and post-acquisition status (June 2026) suggest potential restructuring, redundancy, or organizational consolidation that could disrupt hiring and advancement.

Generated by Claude from KalVista Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Generic formulation post-LOE; mature market with competitive pricing pressure.

Aminocaproic acid tablets

Post-LOE

Another Post-LOE generic variant; incremental differentiation minimal.

Post-LOE

Third Post-LOE generic entry; commodity market saturation.

Post-LOE

Fourth Post-LOE variant; continued generic competition.

Metoclopramide hydrochloride

Post-LOE

Fifth Post-LOE entry; mature, low-margin indication.

Vomiting (chemotherapy, postoperative, nasogastric suction avoidance)

Post-LOE

Post-LOE generic; off-patent market with limited growth.

Severe, persistent pain; opioid addiction

Post-LOE

Sixth generic variant; commoditized indication with minimal differentiation.

Methadone hydrochloride

Post-LOE

Post-LOE generic opioid; mature market with regulatory oversight and abuse potential.

Pipeline & Clinical Trials

Sebetralstat

N/A

Clinical Trials (1)

NCT06628713Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

N/A

Inapplicable

N/A

Clinical Trials (1)

NCT07009262A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

N/A

Sebetralstat

N/A

Clinical Trials (2)

NCT07654829Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

Phase 4

NCT07216378Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

KVD900

PHASE_1

Clinical Trials (1)

NCT04349800A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

Phase 1

KVD824 Prototype 1 modified-release tablet

PHASE_1

Clinical Trials (1)

NCT05118958Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Phase 1

KVD001 Injection

Diabetic Macular Edema

PHASE_1

Clinical Trials (1)

NCT02193113A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

Phase 1

KVD824

PHASE_1

Clinical Trials (1)

NCT05178355A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Phase 1

KVD900

Angioedema, Hereditary, Types I and II

PHASE_2

Clinical Trials (1)

NCT04208412A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Phase 2

KVD001 Injection

Diabetic Macular Edema

PHASE_2

Clinical Trials (1)

NCT03466099Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Phase 2

KVD824

PHASE_2

Clinical Trials (1)

NCT05055258A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

Phase 2

KVD900 600 mg

PHASE_3

Clinical Trials (1)

NCT05505916An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Phase 3

Placebo

PHASE_3

Clinical Trials (1)

NCT05259917A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Phase 3

KVD900 150 mg

PHASE_3

Clinical Trials (1)

NCT06467084Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Phase 3

KVD900 600 mg